Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2015 Nov 30;15(1):72–83. doi: 10.1158/1535-7163.MCT-15-0600

Figure 7. ML264 treatment reduced the expression levels of KLF5 and EGR1 in DLD-1-derived tumor xenografts.

Figure 7

(A) Representative immunohistochemistry staining of KLF5 in DLD-1-derived xenografts treated with vehicle (left panel) and treated with ML264 twice per day at 25mg/kg (right panel) for ten days. (B) Western blot analysis (top panel) and the quantitative analysis (bottom panel) of KLF5 levels in DLD-1-derived xenografts treated with vehicle and treated with ML264 twice per day at 10mg/kg and 25mg/kg for ten days. Results shown from three independent experiments. Data represent mean ± S.D. (n=3). *p < 0.05. (C) Representative immunohistochemistry staining of EGR1 in DLD-1-derived xenografts treated with vehicle (left panel) and treated with ML264 twice per day at 25mg/kg (right panel) for ten days. (D) Immunofluorescence staining of Ki-67 (proliferative marker). Top panel – vehicle treated mice, Bottom panel – ML264-treated mice. (E) Quantitative representation of (D). Three fields were counted for each condition. Data represent mean ± S.D. (n=3). ***p < 0.001.